Bisphosphonates in the Treatment of Bone Diseases
- 12 December 1996
- journal article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 335 (24) , 1836-1837
- https://doi.org/10.1056/nejm199612123352409
Abstract
Bisphosphonates are drugs that inhibit bone turnover by decreasing the resorption of bone. They do this both directly, by inhibiting the recruitment and function of osteoclasts (the bone-resorbing cells), and indirectly, by stimulating osteoblasts (the bone-forming cells), to produce an inhibitor of osteoclast formation. Bisphosphonates may also shorten the life span of osteoclasts. The bisphosphonate compounds available in at least one country include etidronate, clodronate, pamidronate, tiludronate, alendronate, and ibandronate. Although these compounds differ markedly in potency, they share common properties: they are poorly absorbed from the gastrointestinal tract and are concentrated in bone, where they remain until the bone . . .Keywords
This publication has 7 references indexed in Scilit:
- Efficacy of Pamidronate in Reducing Skeletal Complications in Patients with Breast Cancer and Lytic Bone MetastasesNew England Journal of Medicine, 1996
- Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro.Journal of Clinical Investigation, 1996
- Efficacy of Pamidronate in Reducing Skeletal Events in Patients with Advanced Multiple MyelomaNew England Journal of Medicine, 1996
- Effect of Oral Alendronate on Bone Mineral Density and the Incidence of Fractures in Postmenopausal OsteoporosisNew England Journal of Medicine, 1995
- Long-term effects of intravenous pamidronate in fibrous dysplasia of boneThe Lancet, 1994
- Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer.Journal of Clinical Oncology, 1993
- Intermittent Cyclical Etidronate Treatment of Postmenopausal OsteoporosisNew England Journal of Medicine, 1990